FIELD: medicine.
SUBSTANCE: proposed group of inventions relates to medicine. Method and kit for determining the presence of cancer in a subject, comprising determining the concentration of Hsp90α in a plasma sample of the subject. Disclosed is the use of EDTA-K2 as an anticoagulant when sampling plasma for the determination of Hsp90α.
EFFECT: proposed group of inventions provides an increase in the sensitivity and specificity of cancer diagnosis in a subject in the range of Hsp90α concentrations from 56 to 82 ng/ml.
11 cl, 15 dwg, 51 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN SIGNATURE FOR DIAGNOSING COLORECTAL CANCER OR ITS PRECANCEROUS STAGE | 2020 |
|
RU2830580C2 |
| NOVEL TUMOUR BIOMARKER | 2010 |
|
RU2567005C2 |
| NEW TUMOUR BIOMARKER | 2010 |
|
RU2714750C2 |
| METHOD OF APPLYING INFORMATION ON A COMPLEX GROUP OF BIOMARKERS FOR DIAGNOSING A MALIGNANT LUNG TUMOR IN SUBJECT, DIAGNOSTIC KIT AND COMPUTER SYSTEM USING IT | 2017 |
|
RU2687578C2 |
| METHOD FOR IN VITRO DIAGNOSIS OR PREDICTION OF COLORECTAL CANCER OR ITS PRECANCEROUS STAGE | 2020 |
|
RU2831090C2 |
| TUMOUR MARKER, REAGENT FOR DETECTING METHYLATION, KIT AND APPLICATION THEREOF | 2019 |
|
RU2775177C1 |
| TUMOUR MARKER, REAGENT FOR DETECTING METHYLATION, KIT AND APPLICATION THEREOF | 2019 |
|
RU2770928C1 |
| SYSTEM AND METHOD FOR SCREENING THE PROBABILITY OF HAVING COLORECTAL CANCER | 2018 |
|
RU2698854C1 |
| BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS | 2014 |
|
RU2658601C2 |
| MIRNA DEFINITION PLASMA FOR DETECTION OF EARLY STAGES OF COLORECTAL CANCER | 2012 |
|
RU2611189C2 |
